DEALS: Teva buys CoGenesys for $400M


Teva buys CoGenesys for $400M


DEALS

WHO

WITH

WHAT

SCOOP

Pfizer

Washington University

$25M

Washington University and Pfizer researchers will identify, design and execute projects focused on immuno-inflammatory disorders such as arthritis, asthma and diabetes.

Forest Laboratories

Novexel's

$109.6 million

Forest gains development rights to Novexel's intravenous beta lactamase inhibitor, NXL 104, in combination with Forest's ceftaroline.

Teva

CoGenesys

$400 million

Teva says the buyout will give it a better position to compete in the fledgling biogeneric field.

 

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.